{"entity":{"id":"john-haanen","kind":"person","name":"John Haanen","aka":[],"tldr":"John Haanen led the first randomised phase 3 trial of TIL therapy, which beat ipilimumab in melanoma.","summary":"John Haanen is a medical oncologist at the Netherlands Cancer Institute (NKI-AvL) and Professor at Leiden University Medical Center. His specialisms are melanoma, TIL therapy and immunotherapy. He led the first randomised phase 3 trial of tumour-infiltrating lymphocyte therapy, a Dutch and Danish study comparing TIL treatment with ipilimumab in advanced melanoma, reported in the New England Journal of Medicine, in which the cell therapy beat ipilimumab on progression-free survival. He also helped write the ESMO guidelines on immunotherapy toxicity. His record links him to lifileucel and ipilimumab, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haanen%20JB%5BAuthor%5D%20tumor-infiltrating%20lymphocytes"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel","ipilimumab"],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Netherlands Cancer Institute; Professor, Leiden University Medical Center","institutionId":"nki","specialisms":["Melanoma","TIL therapy","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haanen%20JB%5BAuthor%5D%20tumor-infiltrating%20lymphocytes"}],"papers":[{"title":"Treatment with tumor-infiltrating lymphocytes or ipilimumab in advanced melanoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2210233"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"},{"title":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2402604","doi":"10.1056/NEJMoa2402604"},{"title":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2400634","doi":"10.1056/NEJMoa2400634"}],"orcid":"0000-0001-5884-7704"},"route":"/people/john-haanen/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}],"institution":[{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/"},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"idea":[{"id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/"},{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/"}],"paper":[{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/"},{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/"},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/"},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/"}]}}